Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD

Most cardiovascular lipid research has been conducted in the general population; patients with chronic kidney disease face a distinct metabolic and vascular biology that complicates direct extrapolation. This prospective study used nearly 9,300 CKD patients to test whether apolipoprotein B and triglyceride-rich lipoproteins predict atherosclerotic events in this high-risk population.

ApoB was independently associated with atherosclerotic vascular events (HR 1.19 per standard deviation), as were plasma triglycerides and triglyceride-rich lipoprotein cholesterol. Strikingly, these same markers showed inverse associations with non-atherosclerotic vascular events — a divergence that validates the atherogenic specificity of the signal rather than reflecting general vascular fragility.

CKD patients are frequently undertreated for dyslipidemia partly due to uncertainty about whether standard lipid markers apply in the context of altered lipoprotein metabolism. This study demonstrates that the apoB-atherosclerosis relationship is preserved in CKD — extending the clinical rationale for apoB-directed lipid assessment and treatment to this population where cardiovascular risk is already elevated by the kidney disease itself.

We rate the evidence strong. A well-powered prospective cohort validating the clinical relevance of apoB and triglyceride-rich lipoprotein measurement in CKD — a population where the cardiovascular evidence base has historically been thinner than in the general population.